CSF3 and Sepsis: FLAG (FLA+G-CSF) with bortezomib is particularly appealing due to both the high remission rates (morphological remission of 92% and negative MRD of 61%) and minimal gut toxicity in a heavily pretreated patient population, thus minimizing the risk of bacterial translocation and subsequent sepsis.